Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment

Next Previous
X
Search
Trial Profile

A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EIK 1001 (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Birdie Biopharmaceuticals; Eikon Therapeutics

    • Most Recent Events

    • 15 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2021 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2021 According to a Seven and Eight Biopharmaceuticals media release, first patient has been treated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top